Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2012-04-20 | John P. Richard ... Age 54 ... Position: Class II Director ... The current members of the Audit Committee are Mr. Blixt, Mr. Burrill and Mr. Richard ... 2011 DIRECTOR COMPENSATION TABLE ... John P. Richard ... Total ($) 128,478 |
| 2013-04-17 | John P. Richard ... Age 55 ... Position Class II Director ... The current members of the Audit Committee are Mr. Blixt, Mr. Burrill and Mr. Richard ... The current members of the Compensation Committee are Dr. Barrett, Ms. Brown, Dr. Dunton and Mr. Richard ... 2012 Director Compensation Table ... John P. Richard ... Total ($) 53,975 |
| 2014-04-18 | John P. Richard ... 56 ... Chairman of the Board; Class II Director ... The current members of the Governance and Nominating Committee are Mr. Blixt, Ms. Brown and Dr. De Souza ... The current members of the Audit Committee are Mr. Blixt, Dr. De Souza and Mr. Richard ... The current members of the Compensation Committee are Ms. Brown, Dr. Dunton and Mr. Richard ... John P. Richard ... 52,500 ... 44,750 ... 97,250 |
| 2015-11-23 | John P. Richard ... In 2013, Mr. Richard was elected non-executive Chairman of the Targacept board of directors effective January 1, 2014 ... 2014 Director Compensation Table ... John P. Richard ... Total 194,475. |
| 2016-04-25 | John P. Richard | 58 | Class II | Audit Committee Member and Governance and Nominating Committee Chair ... The current members of the Audit Committee are Mr. Lawlor, who serves as Chairman, Dr. Himawan and Mr. Richard. |
| 2017-01-12 | Directors and Named Executive Officers ... John P. Richard 65,334 |
| 2017-05-18 | "John P. Richard 59 Class II Director, and Audit Committee Member and Governance and Nominating Committee Chair" and "John P. Richard 50,000 ... 58,922" |
| 2018-05-11 | "John P. Richard ... 60 ... Audit Committee Chair and Governance and Nominating Committee Member" and "John P. Richard ... Total 85,086" |
| 2019-05-02 | John P. Richard 61 II Audit Committee Chair, and Governance and Nominating Committee Member ... Mr. Richard has served as a member of our Board from November 2002. |
| 2020-05-01 | In 2019, the Audit Committee consisted of Mr. Richard, who served as Chairman, and Messrs. Lawlor and Williams. Director Compensation for Fiscal Year 2019: John P. Richard total $87,421. |
| Filing Date | Source Excerpt |
|---|---|
| 2013-10-01 | John P. Richard, age 56, has served as a member of our Board of Directors since August 2013. ... Mr. Richard’s extensive executive, venture capital and business development experience, having led that function at several life science companies and establishing numerous pharmaceutical alliances, led to the conclusion that he should serve on the Company’s Board of Directors. ... Nominating and Corporate Governance Committee Member. ... Director Compensation Table does not list compensation for Mr. Richard. |
| 2014-10-03 | John P. Richard, age 57, has served as a member of the Company’s Board of Directors since August 2013. Mr. Richard is currently an Operating Partner and non-executive director of Phase4 Partners, a venture capital firm based in London, UK. |
| 2015-09-30 | The members of the Company’s Audit Committee are Ms. VanLent (Chair), Mr. Dougherty and Mr. Richard. |
| 2016-09-27 | John P. Richard, age 59, has served as a member of the Company’s Board of Directors since August 2013. ... Mr. Richard’s extensive executive, strategic, financial and business development experience within the biotechnology industry, and having led the business development function at several companies resulting in numerous pharmaceutical alliances, led to the conclusion that he should serve on the Company’s Board of Directors. |
| 2018-02-26 | John P. Richard has served as a member of the board of directors since 2013. For fiscal 2018, he serves on the Audit and Compensation Committees. Director Compensation 2017: $60,815. |
| 2019-03-11 | John P. Richard has served as a member of our board of directors since 2013. Mr. Richard is co-founder and Head of Corporate Development for Mereo BioPharma Group plc, a London-based biopharmaceutical company started in 2015. |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-05-06